Two top American Senators, Rick Scott and Kirsten Gillibrand, have written to the Department of War Secretary Pete Hegseth, expressing concerns about vulnerabilities in the US pharmaceutical supply chain. They highlighted the heavy reliance on foreign sources, particularly China and India, which could pose risks to military readiness and national security. The Senators requested information on how the Department is addressing risks associated with key pharmaceutical materials and generic drugs used by service members and veterans.
The US Senate Special Committee on Aging, led by Scott and Gillibrand, is investigating the risks that vulnerable pharmaceutical supply chains pose to public health and national security. They emphasized the importance of ensuring access to lifesaving medicines for service members and veterans. With an estimated 91% of prescriptions in the US being generic drugs, the Senators pointed out the significant reliance on these medications by Americans for various health needs.
China and India play crucial roles in producing key pharmaceutical materials essential for domestic drug manufacturing. The Senators raised concerns about the limited oversight and control the US has over foreign sourcing and manufacturing of these materials, highlighting a vulnerability in the pharmaceutical supply chain. They also noted instances where the FDA granted exemptions for drugs or ingredients from factories with substandard conditions, potentially allowing unsafe products into the US market.
Geopolitical instability, such as export restrictions imposed by China, adds another layer of risk to the pharmaceutical supply chain. The Senators warned about the possibility of disruptions in pharmaceutical exports during diplomatic or trade conflicts, which could impact patient care and public health. Urging for domestic procurement of essential medications, they emphasized the need for transparency in labeling pharmaceuticals’ country of origin to provide clarity to consumers and healthcare providers.
